Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MP07-66 is a novel FTY720-analog devoid of immunosuppressive effects leads to the reactivation of PP2A, which in turn triggers apoptosis of CLL cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 80.00 | |
5 mg | In stock | $ 213.00 | |
10 mg | In stock | $ 347.00 | |
25 mg | In stock | $ 589.00 | |
50 mg | In stock | $ 842.00 | |
100 mg | In stock | $ 1,160.00 | |
500 mg | In stock | $ 2,330.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 235.00 |
Description | MP07-66 is a novel FTY720-analog devoid of immunosuppressive effects leads to the reactivation of PP2A, which in turn triggers apoptosis of CLL cells. |
In vitro | CLL cells were incubated with increasing concentrations of MP07-66 (0-16 μM) for 24 and 48 hours and then subject to annexin V–PI flow cytometry. The level of apoptosis reached 50% and 80%, at 24 hours and 48 hours, respectively, at a MP07-66 concentration as high as 16 μM, which paralleled PARP cleavage, a marker of caspase-dependent apoptosis. In addition, the phosphorylation status of PP2A targets, namely Akt, GSK-3, and SHP-1, was negatively affected by the treatment with MP07-66, triggering known downstream events promoting apoptosis, such as Mcl-1 degradation and caspase-3 activation[1]. |
Molecular Weight | 323.47 |
Formula | C19H33NO3 |
CAS No. | 1938056-90-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (772.87 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MP07-66 1938056-90-6 Metabolism Phosphatase MP0766 chronic lymphocytic leukemia FTY720 analogue Inhibitor SET-PP2A complex inhibit immunosuppressive effects MP-07-66 MP07 66 antitumor effects inhibitor